

VALNEVA SE

World Trade Center Lyon
Tour Oxygène
10-12 boulevard Marius Vivier Merle
69007 Lyon, France

Valneva Announces the Availability of Documentation for its Meetings of Shareholders

Lyon (France), June 8, 2017 – The Shareholders of Valneva SE (“Valneva” or “the Company”), are invited to participate in the Company’s Combined General Meeting to be held on June 29, 2017 at 2:30 p.m. CET, at the Novotel Lyon Confluence, 3 rue Paul Montrochet, 69002 Lyon, France.

The Combined General Meeting will follow a Special Meeting of Convertible Preferred Share¹ holders to be held at the same location at 2:00 p.m. that same day.

The preliminary notice of meetings containing the agenda, the proposed resolutions and instructions for participation and voting was published in the Bulletin des Annonces Légales Obligatoires (BALO) on May 22, 2017. Documents and information relating to the meetings are available on Valneva’s website (please refer to this link www.valneva.com/en/investors-media/agm).

In accordance with applicable law, registered shareholders can, by letter, fax or email, request the Company to provide the meeting documents listed in the French commercial code until the fifth working day before the meetings (please refer to the contact details below).

Holders of bearer shares may exercise this right on condition that they provide a certificate of share ownership issued by an authorized financial institution.

Shareholders may also have access to the documents at the below-mentioned address or the Company’s registered office.

Contacts

Valneva SE,
Legal Department,
6 rue Alain Bombard,
44800 Saint Herblain, France
Fax: +33 2 28 07 37 11
Email: assemblée.générale@valneva.com

¹ Convertible Preferred Shares (ISIN: XFCS00X0I9M1) are special instruments created in 2015 and held by Senior Management. They are not to be confused with the *Pseudomonas*-related preferred shares (ISIN: FR0011472943) created in 2013.



Contacts Valneva SE

Laetitia Bachelot Fontaine
Head of Investor Relations &
Corporate Communications
T +33 (0)2 2807 1419
M +33 (0)6 4516 7099
investors@valneva.com

Nina Waibel
Corporate Communications Specialist
T +43 1206 201 149
M +43 6768 455 6719
communications@valneva.com

About Valneva SE

Valneva is a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines.

The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

Valneva's portfolio includes two commercial vaccines for travelers: IXIARO[®]/JESPECT[®] indicated for the prevention of Japanese encephalitis and DUKORAL[®] indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company's value proposition and include vaccines being developed using Valneva's innovative and validated technology platforms (EB66[®] vaccine production cell line, IC31[®] adjuvant).

Valneva shares are tradable on Euronext-Paris, the Vienna stock exchange and Deutsche Börse's electronic platform Xetra[®]. The Company has operations in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. More information is available at www.valneva.com.

Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing and completion of research, development and clinical trials for product candidates, the ability to manufacture, market, commercialize and achieve market acceptance for product candidates, the ability to protect intellectual property and operate the business without infringing on the intellectual property rights of others, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements and needs for additional financing. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement

expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing the information in these materials as of the date of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.